Chemotherapy‐induced peripheral neuropathy onset is associated with early risk of depression and anxiety in breast cancer survivors. (13th July 2022)

• Record Type: Journal Article
• Authors: McNeish, Brendan L.; Richardson, James K.; Whitney, Daniel G.
• Is Part Of: European journal of cancer care. Volume 31:Number 6(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-07-13
• Subjects: breast cancer -- chemotherapy -- psychological -- quality of life -- supportive care; Cancer -- Nursing -- Periodicals; 616.994
• DOI: 10.1111/ecc.13648
• Languages: English
• ISSNs: 0961-5423

Abstract

Abstract: Objective: The objective was to assess for an association between chemotherapy‐induced peripheral neuropathy (CIPN) onset and development of depression and anxiety in breast cancer (BrCa) survivors. Methods: A retrospective observational cohort was used and identified from Optum's De‐identified Clinformatics® Data Mart Database years 2012–2015. Three groups of women were derived based on BrCa and CIPN status: BrCa+/CIPN+ ( n = 244), BrCa+/CIPN− ( n = 8870), and BrCa−/CIPN− ( n = 1, 125, 711). The ratio of the prevalence ratios (RPR) determined if the change in risk of depression and anxiety from the 12‐month preindex period to postindex period I (0–6 months) and II (7–12 months) was different for BrCa+/CIPN+ compared to BrCa+/CIPN− and BrCa−/CIPN−. Results: The adjusted RPR for depression was significantly elevated for BrCa+/CIPN+ compared to BrCa+/CIPN− and BrCa−/CIPN− for postindex periods I (RPR = 1.35 [1.10, 1.65] and 1.33 [1.08, 1.63], respectively) and II (RPR = 1.53 [1.21, 1.94] and 1.50 [1.17, 1.93], respectively). The RPR for anxiety was significantly elevated for BrCa+/CIPN+ compared to BrCa+/CIPN− and BrCa−/CIPN− for postindex periods I (RPR = 1.37 [1.12, 1.67] and 1.31 [1.06, 1.61], respectively) and II (RPR = 1.41 [1.13, 1.76] and 1.28 [1.02, 1.62], respectively). Conclusions: Among BrCa survivors, CIPN onset is associated with a subsequent increased 12‐month risk of depression and anxiety. Depression and anxiety screening should be considered in BrCa+/CIPN+ survivors, particularly given their known impact on fall risk. The observed association between CIPN and an increased risk of depression and anxiety should be further studied in prospective studies.